Reimagining the Future of Genetic Testing

Revolutionizing the preimplantation genetic testing laboratory allowing for greater access, accuracy, and clinical impact

Transforming Genetic Testing with Experience and Innovation

At NOVA Genomics, we are reimagining preimplantation genetic testing (PGT). Founded by industry veterans Dr. Gary Harton and Cynthia Hudson, NOVA brings together cutting-edge technology and a new standard of care to help patients and IVF providers navigate the complexities of genetic testing through informed decision making.

Our team is developing an advanced platform that will serve as the foundation for our contribution to the future of reproductive genetic testing.

UNDERSTANDING PREIMPLANTATION GENETIC TESTING

PGT is a genetic screening test performed on embryos created by in vitro fertilization (IVF). PGT results may be used by physicians in the IVF clinic setting in their clinical decision making.

At NOVA Genomics, we analyze embryos for chromosomal abnormalities, such as extra or missing chromosomes, as well as single-gene disorders and structural chromosomal rearrangements that can lead to inherited genetic conditions.

PGT is offered as three options: PGT-A, PGT-M, and PGT-SR, each designed to address different genetic concerns.

PGT-A

Preimplantation Genetic Testing for Aneuploidy (PGT-A) is a genetic test to screen embryos for numerical chromosome changes (i.e. Down syndrome). This test identifies embryos predicted to have the expected complement of chromosomes.

PGT-SR

Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR) is a genetic test used during IVF to screen embryos for unbalanced chromosomal structures caused by inherited rearrangements like translocations or inversions.

PGT-M

Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) is a genetic test performed on embryos to screen for and diagnose inherited variants that cause monogenic (single-gene) disorders (i.e. cystic fibrosis, sickle cell anemia).

nova genomics: A Modern Approach to Preimplantation Genetic Testing

NOVA Genomics was founded by two pioneers in the IVF industry. Cynthia Hudson and Dr. Gary Harton, who bring over 50 years of combined experience in Embryology and Preimplantation Genetic Testing (PGT). After decades of work, they recognized critical gaps in the field, including outdated lab technologies, growing concerns about quality and compliance, and ongoing debates over the clinical value of PGT.

Their response was to build a next-level PGT lab from the ground up, focused on expanding access to advanced genetic services for families in need of PGT-SR and PGT-M testing for inherited conditions.

our mission

NOVA Genomics exists to transform preimplantation genetic testing by making high-precision, clinically meaningful insights accessible to every IVF journey. We are driven to close the gaps in technology, quality, and equity by building a new model for genetic testing – one rooted in scientific excellence, patient-centered care, and uncompromising standards.

Driven by this mission, NOVA Genomics is transforming the PGT experience through:

leadership
in education

We are committed to educating our customers and the broader community about the science and benefits of PGT. By promoting awareness and understanding, we support informed decision-making throughout the IVF and genetic screening process.

excellence in
genetic counseling

We've partnered with premier GC services to offer our patients unparalleled support and education throughout their journey. With flexible communication options including live consultations and results discussions with certified genetic counselors, patients and providers are supported both before and after testing.

strategic
partnerships

With an industry-leading management team, we are forging strategic partnerships with leading reagent and software providers to guarantee that our patients and clinical partners have access to the most advanced, reliable, and effective tools in reproductive genetics.

innovation
technology platform

We are developing a new and more effective PGT platform that prioritizes high-quality genetic insights. Our focus is on delivering accurate results that put patient needs and scientific integrity at the forefront of fertility care.

Meet the Experts Behind NOVA Genomics

founders

Gary Harton PhD

Chief Scientific Officer

Gary brings 35 years of experience covering embryology and andrology, molecular and classic cytogenetics, next-generation sequencing, and clinical genetics.

Cynthia Hudson

Chief Executive Officer

Cynthia is a medical technologist with over 25 years of experience as an embryologist, entrepreneur, and product specialist.

clinical team

Harvey Stern MD, PhD (FABMGG)

Medical Director

Dr. Stern is a Board-Certified Clinical & Molecular Geneticist specializing in Reproductive Genetics. He has over 30 years of experience as Medical Director of Preimplantation Genetic Testing and Molecular Genetics laboratories.

Mary Sands, MS, CGC

Director of Clinical Services

Mary is a Certified Genetic Counselor specializing in reproductive genetics with over 20 years of experience managing laboratory and clinical integration in the IVF clinic setting.

laboratory team

Brian Mariani PhD

Director Laboratory Services

Brian has conducted extensive research in cell and molecular biology, exploring aspects of gene organization and how genetic information is expressed and regulated in the context of early developmental biology processes.

Khoa Tran

Lab Team Lead SNV

Khoa has 20 years of research and clinical experience applying molecular diagnostics to the field of reproductive genetics.

Veronica Novik PhD

Lab Team Lead CNV

Veronica is a laboratory professional with over two decades of experience in academic research and clinical laboratory leadership. Recently serving as Assistant Director at the Genetics and IVF Institute, she led cutting-edge initiatives in PGT and molecular diagnostics.

Gabrielle Byers

BS Lab Intern

Gabrielle is a current biotechnology graduate student with a background in Biology and a growing foundation in Computational Genomics and Molecular Science.

why choose nova genomics?

NOVA Genomics’ founders benefit from over 50 years of combined experience in embryology and reproductive genetics, ensuring a profound understanding of the field.

As experts in genetics with over 35 years of clinical experience, the NOVA Genomics team offers best in class genetic testing options for patients in need of PGT-M, PGT-SR and PGT-A.

Recognizing the importance of equitable healthcare, NOVA Genomics emphasizes expanding access to advanced genetic services, particularly for underserved communities.

NOVA Genomics prioritizes clarity and integrity in its operations, ensuring that patients and clinics receive straightforward, trustworthy information.

Unlike many competitors that have evolved from existing frameworks, NOVA Genomics was designed from the ground up to address specific gaps in PGT, focusing on modern technology, quality, and compliance.

By leveraging the latest advancements in genetic testing, NOVA Genomics ensures high accuracy and reliability in its results, setting a new standard in the industry.

Understanding the nuances of IVF treatments, NOVA Genomics works closely with clinics to provide seamless integration of its testing services, enhancing overall patient care.

RESOURCES

Connect with our team of experts to learn more about PGT and IVF support